SMSophie Mutel

Sophie Mutel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sophie Mutel has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Augusto J. Mendes

    Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland

    2 shared publications
  • Chen Wang

    Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland

    2 shared publications
  • Daniele Altomare

    Department of Business Economics, Health and Social Care (DEASS), Competence Centre on Ageing (CCA), University of Applied Sciences and Arts of Southern Switzerland (SUPSI), Manno, Switzerland

    2 shared publications
  • Federica Ribaldi

    Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland

    2 shared publications
  • Valentina Garibotto

    Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocentre and Faculty of Medicine, University of Geneva, Geneva, Switzerland

    2 shared publications
  • Augusto J. Mendes

    Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, 1205 Geneva, Switzerland

    1 shared publication

Latest Publications

  • Open Access

    Optimal amyloid and tau CSF biomarkers for the detection of amyloid and tau PET positivity in a memory clinic population

    by Sophie Mutel, Federica Ribaldi, Augusto J. Mendes, Daniele Altomare, Cecilia Boccalini, Claire Chevalier, Miguel A. Frias, Ilse Kern, Moira Marizzoni, Debora Peretti, et al.

    Background: Accurate detection of Alzheimer’s disease (AD) pathophysiological changes is crucial for research and clinical practice. While positron emission tomography (PET) imaging is an established reference standard for detecting brain amyloid and tau deposition, cerebrospinal fluid (CSF) biomarkers offer a more accessible alternative. This study aimed to identify optimal CSF biomarkers and thresholds for predicting tau and amyloid PET positivity in a memory clinic population. Methods: This cross-sectional, observational study included 220 participants from a memory clinic who underwent amyloid or tau PET scans and CSF biomarker analysis using either Fujirebio INNOTEST or LUMIPULSE assays. CSF biomarker performance was assessed via receiver operating characteristic (ROC) analysis. Double-threshold approaches were implemented to address classification uncertainty. Results: Ratios combining biomarkers of both amyloid and tau, such as Aβ42/pTau, consistently outperformed individual biomarkers in detecting amyloid and tau PET positivity. For amyloid PET, the Aβ42/pTau ratio achieved an AUC of 0.93 (95% CI: 0.86–0.99) with INNOTEST and an AUC of 0.89 (95% CI: 0.8–0.98) with LUMIPULSE. For tau PET, the Aβ42/pTau ratio achieved an AUC of 0.85 (95% CI: 0.77–0.93) with INNOTEST and an AUC of 0.97 (95% CI: 0.9-1.00) with LUMIPULSE. Double thresholds enabled classification based on predefined sensitivity and specificity, and can be used by clinicians to quickly assess a subject’s likelihood of positivity based on their biomarker levels. Discussion: CSF biomarker ratios such as Aβ42/pTau provide high predictive accuracy for brain amyloid and tau deposition. Implementing double thresholds enhances clinical utility by highlighting ambiguous cases requiring further assessment.

  • Open Access

    Exploring the Preventive Effects of Omega-3 Polyunsaturated Fatty Acids Supplementation on Global Cognition: A Systematic Review and Meta-Analysis of Cognitively Unimpaired Older Adults

    by Roberta Mulargia, Federica Ribaldi, Sophie Mutel, Ozge Sayin, Giorgi Khachvani, Gabriele Volpara, Giulia Remoli, Umberto Nencha, Stefano Gianonni-Luza, Stefano Cappa, et al.

    Dementia prevention is a global public health priority, and lifestyle interventions, including nutrition, have gained interest for their potential to maintain cognitive health. Among nutritional interventions, omega-3 polyunsaturated fatty acids (n-3 FA), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been widely studied for their potential to support cognitive health. This systematic review evaluated whether n-3 FA supplementation improves global cognition in cognitively unimpaired older adults. Nineteen randomized controlled trials (RCTs) met inclusion criteria, of which five reported significant improvements in global cognition. A random-effects meta-analysis of 11 placebo-controlled RCTs showed no significant effect (SMD = −0.02, 95% CI: −0.07 to 0.04). Heterogeneity in supplement type, dosage, duration, and outcome measures may have contributed to inconsistent findings and limited comparability. Furthermore, methodological quality of the trials was generally low. While current evidence does not demonstrate a significant effect of n-3 FA supplementation on global cognition, future research should prioritize well-powered, longer-duration RCTs that incorporate biomarker monitoring and more appropriate doses. Clarifying the role of n-3 FA in cognitive aging remains essential for informing nutrition-based dementia prevention strategies.

  • Open Access

    Resilience in Alzheimer's disease: Impact of operationalization and methodological choices

    by Sophie Mutel, Lara Quatrocchi, Daniele Altomare, Christian Chicherio, Max Scheffler, Karl‐Olof Lövblad, Kaj Blennow, Nicholas J. Ashton, Henrik Zetterberg, Marc Abramowicz, et al.

    INTRODUCTION: Resilience, the ability to maintain cognition or brain integrity despite Alzheimer's disease (AD) pathology, is often quantified using the residual approach. However, the variability in methodology and correction methods for this approach raises concerns about the interpretability of findings across studies.METHODS: We assessed brain resilience (BR) and cognitive resilience (CR) in a memory clinic population using the residual approach. We compared non‐corrected and corrected residuals’ associations with risk factors using linear regression models, and their impact on longitudinal cognition using linear mixed‐effects models.RESULTS: Corrected versus non‐corrected BR yielded distinct, often opposing, associations. For example, glial fibrillary acidic protein (GFAP) was negatively associated with non‐corrected BR (β = –0.33; p < 0.01) but positively with corrected BR (β = 0.5, p < 0.001). Only corrected CR measures yielded significant associations. Only corrected residuals predicted cognitive decline.DISCUSSION: The observed discrepancies raise questions about the reliability of the residual approach in accurately capturing resilience.Highlights: Corrected and non‐corrected residuals show distinct associations with risk factors. Corrected and non‐corrected residuals show different predictions of cognitive decline. These approaches may reflect general brain health rather than true resilience mechanisms.